Professional Documents
Culture Documents
12394
BJP Pharmacology
www.brjpharmacol.org
Keywords
Russell H Swerdlow Alzheimer’s disease; cancer;
glycolysis; law of mass action;
Departments of Neurology, Molecular and Integrative Physiology, and Biochemistry and mitochondria; neurodegeneration
Molecular Biology, University of Kansas School of Medicine, Kansas City, KS USA, and ----------------------------------------------------------------
Alzheimer’s Disease Center, University of Kansas Medical Center, Fairway, KS, USA Received
6 July 2013
Revised
17 August 2013
Accepted
22 August 2013
Here we discuss a specific therapeutic strategy we call ‘bioenergetic medicine’. Bioenergetic medicine refers to the
manipulation of bioenergetic fluxes to positively affect health. Bioenergetic medicine approaches rely heavily on the law of
mass action, and impact systems that monitor and respond to the manipulated flux. Since classically defined energy
metabolism pathways intersect and intertwine, targeting one flux also tends to change other fluxes, which complicates
treatment design. Such indirect effects, fortunately, are to some extent predictable, and from a therapeutic perspective may
also be desirable. Bioenergetic medicine-based interventions already exist for some diseases, and because bioenergetic
medicine interventions are presently feasible, new approaches to treat certain conditions, including some neurodegenerative
conditions and cancers, are beginning to transition from the laboratory to the clinic.
LINKED ARTICLES
This article is part of a themed issue on Mitochondrial Pharmacology: Energy, Injury & Beyond. To view the other articles in
this issue visit http://dx.doi.org/10.1111/bph.2014.171.issue-8
Abbreviations
AChEI, acetylcholine esterase inhibitor; AD, Alzheimer’s disease; AMPK, AMP kinase; CoQ, coenzyme Q; COX,
cytochrome oxidase; cybrid, cytoplasmic hybrid; DM, diabetes mellitus; ER, endoplasmic reticulum; ETC, electron
transport chain; FA, Friedreich’s ataxia; FAD, flavin adenine dinucleotide; FDG PET, fluorodeoxyglucose PET; HD,
Huntington’s disease; IP3, inositol triphosphate; MCI, mild cognitive impairment; MCT, monocarboxylate transporter;
mtDNA, mitochondrial DNA; mTOR, mammalian target of rapamycin; NAA, n-acetyl aspartate; OAA, oxaloacetate; PD,
Parkinson’s disease; PDHC, pyruvate dehydrogenase complex; PDK4, pyruvate dehydrogenase kinase 4; PGC1,
peroxisome proliferator-activated receptor γ-complex 1; SERCA, sarcoendoplasmic reticulum calcium ATPase
Bioenergetics refers to the chemistry and molecular physiol- diseases and cancer (Swerdlow, 2009b; Vander Heiden et al.,
ogy of energy metabolism. It is most often considered at the 2009; Chaturvedi and Beal, 2013). In some disorders, bioen-
individual cell level, with a cell’s bioenergetic status typically ergetic perturbations are etiologically relevant. In others, bio-
summarized as the amount of energy-yielding intermediates, energetic changes induced by upstream pathologies mediate
such as ATP, it contains. The balance between a cell’s rate of or amplify a particular phenotype or pathology. Mitochon-
energy intermediate production and consumption determine drial dysfunction is frequently seen, and diseases in which
this parameter. mitochondria appear to play particularly upstream roles are
Multiple biochemical pathways contribute to a cell’s bio- sometimes considered ‘mitochondriopathies’ (Swerdlow,
energetic state. Within cells, these pathways are variably 2009a; Swerdlow, 2009b). Mitochondrial and bioenergetic
compartmentalized or span compartments, and bioenergetic dysfunctions often coincide, as mitochondrial dysfunction
pathways are ultimately characterized by the passage of tends to cause bioenergetic dysfunction.
carbon that starts as part of one molecule and ends as ‘Mitochondrial medicine’ refers to the art and science of
another. Bioenergetic pathways, therefore, are characterized correcting mitochondrial dysfunction or minimizing the
by movement through the pathway, or as a ‘flux’. consequences of mitochondrial dysfunction (Luft, 1994;
Bioenergetic changes occur in many diseases, including Swerdlow, 2009a; Swerdlow, 2011b). Data increasingly indi-
the mitochondrial encephalomyopathies, neurodegenerative cate one can manipulate mitochondria indirectly, or mitigate
1854 British Journal of Pharmacology (2014) 171 1854–1869 © 2013 The British Pharmacological Society
14765381, 2014, 8, Downloaded from https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.12394 by Cochrane Colombia, Wiley Online Library on [28/09/2023]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
Bioenergetic medicine
BJP
the impact of mitochondrial failure, by manipulating bioen- Bioenergetic fluxes: A brief overview
ergetic pathways that lie external to the mitochondria or, for
pathways that traverse the mitochondria, at steps that lie This section briefly reviews several major bioenergetic
outside the mitochondria themselves. This currently feasible pathways, some of which are summarized in Figure 1. The
overall strategy also impacts non-mitochondrial bioenergetic glycolysis, Krebs and oxidative phosphorylation pathways
parameters, as well as the expression of genes that monitor facilitate carbohydrate-based energy production. Glycolysis
and respond to a cell’s overall bioenergetic state. These effects allows for anaerobic ATP generation, and occurs in the
can fundamentally affect cell health and viability. This review cytosol. Within the mitochondria, conversion of pyruvate to
considers the complexities and potential of bioenergetic acetyl CoA, followed by a full turn of the Krebs cycle, reduces
flux manipulation or, to introduce a term, ‘bioenergetic NAD+ to NADH and FAD to FADH2. Cytosolic NADH, which
medicine’, for the treatment of various disorders and is generated during glycolysis, can also supplement this by
conditions. using shuttle systems to transfer ‘reducing equivalents’ to
Figure 1
Some of the major bioenergetic pathways. Glycolysis, the pentose phosphate shunt, the Krebs cycle and gluconeogenesis are illustrated. The large
blue box indicates the mitochondrial compartment; the cytosol is the area outside of this blue box. Redox (green text boxes) and energy storage
(red text boxes) intermediates are indicated. Relationships between these pathways and some amino acids (yellow text boxes, with standard
abbreviations used) are shown. To give a better overall feel for the connectivity between these pathways, some critical shuttles such as the
malate-aspartate shuttle and citrate-malate shuttle are superficially (but incompletely) indicated. High-energy electrons from NADH and FADH2
feed into the respiratory pathway, and combine with O2 to form H2O (not shown). Fatty acid β-oxidation, which produces large amounts of NADH
and acetyl CoA is not shown, although entry of D-β-hydroxybutyrate (a ketone body) carbon into the Krebs cycle is incompletely summarized in
order to show its associated contribution to the mitochondrial redox balance.
Figure 2
Pyruvate flux is influenced by redox states. Upon entering the mitochondrion (shown as a blue box), pyruvate carbon can proceed to acetyl CoA
and the Krebs cycle, or ultimately return to the cytosol. NAD+/NADH ratios influence this branch point, with a high ratio favouring the
PDHC-catalysed reaction. If acetyl CoA accumulates, biotin decarboxylation occurs and pyruvate carboxylase converts pyruvate to OAA. If the
NAD+/NADH ratio remains relatively elevated and ATP levels are low, OAA enters the Krebs cycle (an anaplerotic reaction). If the NAD+/NADH ratio
falls and ATP levels are high, OAA is reduced and the pyruvate carbon returns to the cytosol as malate. In tissues that perform gluconeogenesis,
if the cytosol is adequately reduced and contains adequate ATP, the original pyruvate carbon can proceed through that pathway.
the mitochondrial matrix. The oxidative phosphorylation predictably slow glycolysis flux, while increasing this ratio
pathway, or respiratory chain, oxidizes these reduced dinu- would predictably accelerate glycolysis flux. A reduction in
cleotides, using molecular oxygen as the final electron the mitochondrial NAD+/NADH ratio would predictably slow
acceptor. the Krebs cycle flux while increasing respiratory flux; increas-
Fatty acid catabolism proceeds via β-oxidation, a series of ing this ratio would predictably have the opposite effect.
reactions that occur within mitochondria. This process NAD+/NADH ratios may also influence pyruvate utilization
reduces NAD+ to NADH, FAD to FADH2 and generates acetyl (Figure 2).
CoA. These acetyl groups can enter the Krebs cycle or, under Under conditions of fixed energy expenditure, anaerobic
conditions of excess or low insulin levels, divert towards and aerobic fluxes tend to reciprocally relate. The Pasteur
ketone body formation. effect refers to the observation, initially made in yeast, that
A number of branch points exist that facilitate conserva- enabling respiration reduces fermentation and by extension
tion of carbon and its conversion towards or incorporation glycolysis (Krebs, 1972). The Crabtree effect refers to the
into other molecules. For example, the pentose phosphate observation that enabling glycolysis reduces respiration
shunt diverts glucose towards the production of 5-carbon (Crabtree, 1928). More recently, an effect in which reduced
sugars that are used to generate nucleic acids and nucleotides, glycolysis flux associates with increased respiratory flux was
as well as aromatic amino acid precursor carbons. Also, characterized (Swerdlow et al., 2013). In the tumour cell-
although forward flow through these major bioenergetic observed Warburg effect, relatively high glycolysis and low
fluxes is generally considered from the energy-producing, respiratory flux rates are observed (Warburg, 1956). What
catabolic perspective, the case of gluconeogenesis emphasizes driving forces ultimately underlie these effects is unclear.
that reverse fluxes occur. Obviously, reciprocal relationships such as these help facili-
The law of mass action influences bioenergetic fluxes and tate a constant store of energy, or in other words an energy
flux patterns. Increasing concentrations of upstream metabo- store equilibrium since changes in ATP production in one
lites can drive a flux, while increasing concentrations of arm are offset by opposing ATP production changes in the
downstream metabolites can reduce a flux. For example, other arm.
pyruvate accumulation inhibits glycolysis, a process that may
involve the inhibition of several different glycolytic enzymes
(Williamson and Jones, 1964). When considering the law of Bioenergetics in physiology and health
mass action, redox pairs such as NAD+ and NADH also play a
critical role. Cytosolic NAD+ is needed to support glycolysis Bioenergetic parameters change over the course of develop-
flux. A reduction in the cytosolic NAD+/NADH ratio would ment. For example, bioenergetic fluxes tend to decline with
Figure 3
The tripartite synapse. Glutamate released into the synapse facilitates intercellular communication. To terminate this signal, synaptic glutamate is
co-imported with sodium into an astrocyte. The glutamate in the astrocyte, following its conversion to glutamine, is returned to the pre-synaptic
neuron. The sodium that entered the astrocyte is removed by the sodium-potassium ATPase, which consumes the astrocyte’s ATP. The astrocyte
replaces its ATP by importing glucose from the blood and increasing its glycolysis flux. This produces lactate in the relatively anaerobic astrocytes,
which is exported and taken up by high-affinity MCTs on the neurons. This lactate carbon eventually accesses mitochondria in synaptic boutons,
fuels respiration and generates the ATP needed to restore neuron ion gradients.
advancing age (Navarro and Boveris, 2007; Boveris and The most differentiated tissues, interestingly, are bioener-
Navarro, 2008; Bratic and Larsson, 2013). In the brain, this getically organized in ways that might facilitate such a
includes decreasing glucose utilization, which suggests paradox. For example, in muscle, anaerobic type II fibres
reduced glycolysis flux (De Santi et al., 1995; Willis et al., produce lactate during glycolysis, and export that lactate.
2002; Kalpouzos et al., 2009; Chetelat et al., 2013; Marano Aerobic type I fibres then import the type II fibre-generated
et al., 2013). Mitochondria function less robustly, as illus- lactate and use it as a respiratory fuel. This may create a
trated by falling complex I and IV Vmax activities (Navarro situation in which a reduction of the primary flux in one cell
and Boveris, 2007). The overall picture is somewhat murky, type inadvertently reduces the primary flux of the other cell
and some findings may be tissue-specific, but data argue that type.
at least for a period of time during adulthood, some tissues Considerable data argue a similar arrangement exists in
increase their mitochondrial mass (Barrientos et al., 1997a; brain (Pellerin and Magistretti, 1994; Magistretti and Pellerin,
1997b; Hirai et al., 2001; Manczak et al., 2005). If this truly 1999; Pellerin and Magistretti, 2003; Pierre and Pellerin,
happens in the face of declining electron transport chain 2005); this arrangement is shown in Figure 3. In this scheme,
(ETC) Vmax activities, such changes could represent a com- relatively anaerobic astrocytes generate lactate via glycolysis
pensatory up-regulation (Swerdlow, 2011a). and export that lactate to relatively aerobic neurons, whose
During this stage, mitochondrial DNA (mtDNA) copy respiratory chains use it to produce ATP. This bioenergetic
numbers may increase while mtDNA-encoded mRNA tran- relationship likely plays an especially important role during
script levels decrease (Barrientos et al., 1997b). At some point, action potential-induced synaptic activity, and defines a ‘tri-
though, both the drive to maintain mitochondrial mass as partite synapse’ that functionally differs from the traditional
well as mitochondrial mass itself falls (Manczak et al., 2005). bipartite synapse (Pellerin and Magistretti, 2004; Perea et al.,
The fact that some tissues such as brain exhibit concomitant 2009; Faissner et al., 2010). Recent studies further report
age-related declines in both respiratory capacity and glucose lactate in fact plays a crucial role in memory acquisition
utilization is somewhat paradoxical, since experiments per- (Newman et al., 2011; Suzuki et al., 2011).
formed with cultured cells typically show inverse anaerobic– Relationships between bioenergetic intermediate import
aerobic flux relationships (Swerdlow et al., 2013). and export also exist between separate organs. In the Cori
Di Prospero NA, Baker A, Jeffries N, Fischbeck KH (2007). Gibson GE, Starkov A, Blass JP, Ratan RR, Beal MF (2010). Cause
Neurological effects of high-dose idebenone in patients with and consequence: mitochondrial dysfunction initiates and
Friedreich’s ataxia: a randomised, placebo-controlled trial. Lancet propagates neuronal dysfunction, neuronal death and behavioral
Neurol 6: 878–886. abnormalities in age-associated neurodegenerative diseases. Biochim
Biophys Acta 1802: 122–134.
Dimauro S (2013). Mitochondrial encephalomyopathies – fifty years
on: the Robert Wartenberg Lecture. Neurology 81: 281–291. Gordon PH, Moore DH, Miller RG, Florence JM, Verheijde JL,
Doorish C et al. (2007). Efficacy of minocycline in patients with
DiMauro S, Schon EA (2008). Mitochondrial disorders in the amyotrophic lateral sclerosis: a phase III randomised trial. Lancet
nervous system. Annu Rev Neurosci 31: 91–123. Neurol 6: 1045–1053.
Dorsey ER, Albin RL, Blindauer KA, Chiu E, Colcher A, Greco T, Fiskum G (2010). Neuroprotection through stimulation of
Corey-Bloom J et al. (2013). A randomized, double-blind, mitochondrial antioxidant protein expression. J Alzheimers Dis 20
placebo-controlled study of latrepirdine in patients with mild to (Suppl. 2): S427–S437.
moderate Huntington disease. JAMA Neurology 70: 25–33.
Gu M, Cooper JM, Taanman JW, Schapira AH (1998).
Dumont M, Lin MT, Beal MF (2010). Mitochondria and antioxidant Mitochondrial DNA transmission of the mitochondrial defect in
targeted therapeutic strategies for Alzheimer’s disease. J Alzheimers Parkinson’s disease. Ann Neurol 44: 177–186.
Dis 20 (Suppl. 2): S633–S643.
Guarente L (2007). Sirtuins in aging and disease. Cold Spring Harb
E L, Lu J, Burns JM, Swerdlow RH (2013a). Effect of exercise on Symp Quant Biol 72: 483–488.
mouse liver and brain bioenergetic infrastructures. Exp Physiol 98:
Gutzmann H, Hadler D (1998). Sustained efficacy and safety of
207–219.
idebenone in the treatment of Alzheimer’s disease: update on a
E L, Lu J, Selfridge JE, Burns JM, Swerdlow RH (2013b). Lactate 2-year double-blind multicentre study. J Neural Transm Suppl 54:
administration reproduces specific brain and liver exercise-related 301–310.
changes. J Neurochem. Epub ahead of print.
Handschin C, Spiegelman BM (2006). Peroxisome proliferator-
Eckel RH, Grundy SM, Zimmet PZ (2005). The metabolic syndrome. activated receptor gamma coactivator 1 coactivators, energy
Lancet 365: 1415–1428. homeostasis, and metabolism. Endocr Rev 27: 728–735.
Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS Krishnan KR, Charles HC, Doraiswamy PM, Mintzer J, Weisler R, Yu
et al. (2001). Mitochondrial abnormalities in Alzheimer’s disease. X et al. (2003). Randomized, placebo-controlled trial of the effects
J Neurosci 21: 3017–3023. of donepezil on neuronal markers and hippocampal volumes in
Alzheimer’s disease. Am J Psychiatry 160: 2003–2011.
Holloszy JO (1975). Adaptation of skeletal muscle to endurance
exercise. Med Sci Sports 7: 155–164. Lambert AJ, Wang B, Yardley J, Edwards J, Merry BJ (2004). The
effect of aging and caloric restriction on mitochondrial protein
Howell N (1998). Leber hereditary optic neuropathy: respiratory
density and oxygen consumption. Exp Gerontol 39: 289–295.
chain dysfunction and degeneration of the optic nerve. Vision Res
38: 1495–1504. Langston JW, Ballard P, Tetrud JW, Irwin I (1983). Chronic
Parkinsonism in humans due to a product of meperidine-analog
Hudson G, Nalls M, Evans JR, Breen DP, Winder-Rhodes S,
synthesis. Science 219: 979–980.
Morrison KE et al. (2013). Two-stage association study and
meta-analysis of mitochondrial DNA variants in Parkinson disease. Lu J, E L, Roy N, Hutfles L, Selfridge E, Funk E et al. (2013). Effect of
Neurology 80: 2042–2048. cholinergic signaling on neuronal cell bioenergetics. J Alzheimers
Dis 33: 1135–1146.
Ihara Y, Namba R, Kuroda S, Sato T, Shirabe T (1989).
Mitochondrial encephalomyopathy (MELAS): pathological study Lucia A, Nogales-Gadea G, Perez M, Martin MA, Andreu AL, Arenas
and successful therapy with coenzyme Q10 and idebenone. J (2008). McArdle disease: what do neurologists need to know? Nat
J Neurol Sci 90: 263–271. Clin Pract Neurol 4: 568–577.
Jahani-Asl A, Cheung EC, Neuspiel M, MacLaurin JG, Fortin A, Park Luft R (1994). The development of mitochondrial medicine. Proc
DS et al. (2007). Mitofusin 2 protects cerebellar granule neurons Natl Acad Sci U S A 91: 8731–8738.
against injury-induced cell death. J Biol Chem 282: 23788–23798.
Maassen JA, Janssen GM, t Hart LM (2005). Molecular mechanisms
Jessen F, Traeber F, Freymann K, Maier W, Schild HH, Block W of mitochondrial diabetes (MIDD). Ann Med 37: 213–221.
(2006). Treatment monitoring and response prediction with proton
Maassen JA, t Hart LM, Ouwens DM (2007). Lessons that can be
MR spectroscopy in AD. Neurology 67: 528–530.
learned from patients with diabetogenic mutations in
Joffe GT, Parks JK, Parker WD, Jr (1998). Secondary inhibition of mitochondrial DNA: implications for common type 2 diabetes. Curr
2-ketoglutarate dehydrogenase complex by MPTP. Neuroreport 9: Opin Clin Nutr Metab Care 10: 693–697.
2781–2783.
Magistretti PJ, Pellerin L (1999). Cellular mechanisms of brain
Jones RW (2010). Dimebon disappointment. Alzheimers Res Ther 2: energy metabolism and their relevance to functional brain imaging.
25. Philos Trans R Soc Lond B Biol Sci 354: 1155–1163.
Jung CH, Ro SH, Cao J, Otto NM, Kim DH (2010). mTOR regulation Mancuso M, Orsucci D, Volpi L, Calsolaro V, Siciliano G (2010).
of autophagy. FEBS Lett 584: 1287–1295. Coenzyme Q10 in neuromuscular and neurodegenerative disorders.
Curr Drug Targets 11: 111–121.
Kalpouzos G, Chetelat G, Baron JC, Landeau B, Mevel K, Godeau C
et al. (2009). Voxel-based mapping of brain gray matter volume and Manczak M, Jung Y, Park BS, Partovi D, Reddy PH (2005).
glucose metabolism profiles in normal aging. Neurobiol Aging 30: Time-course of mitochondrial gene expressions in mice brains:
112–124. implications for mitochondrial dysfunction, oxidative damage, and
cytochrome c in aging. J Neurochem 92: 494–504.
Kapahi P, Chen D, Rogers AN, Katewa SD, Li PW, Thomas EL et al.
(2010). With TOR, less is more: a key role for the conserved Manczak M, Calkins MJ, Reddy PH (2011). Impaired mitochondrial
nutrient-sensing TOR pathway in aging. Cell Metab 11: 453–465. dynamics and abnormal interaction of amyloid beta with
Silva DF, Selfridge JE, Lu J, E L, Roy N, Hutfles L et al. (2013). Swerdlow RH, Khan SM (2009). The Alzheimer’s disease
Bioenergetic flux, mitochondrial mass and mitochondrial mitochondrial cascade hypothesis: an update. Exp Neurol 218:
morphology dynamics in AD and MCI cybrid cell lines. Hum Mol 308–315.
Genet 22: 3931–3946. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan
Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, JP et al. (1996). Origin and functional consequences of the complex
Chen W et al. (2001). Positron emission tomography in evaluation I defect in Parkinson’s disease. Ann Neurol 40: 663–671.
of dementia: regional brain metabolism and long-term outcome.
Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS,
JAMA 286: 2120–2127.
Bennett JP, Jr et al. (1997). Cybrids in Alzheimer’s disease: a cellular
Sims NR, Finegan JM, Blass JP, Bowen DM, Neary D (1987). model of the disease? Neurology 49: 918–925.
Mitochondrial function in brain tissue in primary degenerative
Swerdlow RH, Burns JM, Khan SM (2010). The Alzheimer’s disease
dementia. Brain Res 436: 30–38.
mitochondrial cascade hypothesis. J Alzheimers Dis 20 (Suppl. 2):
Srivastava S, Diaz F, Iommarini L, Aure K, Lombes A, Moraes CT S265–S279.
(2009). PGC-1alpha/beta induced expression partially compensates
for respiratory chain defects in cells from patients with Swerdlow RH, E L, Aires D, Lu J (2013). Glycolysis-respiration
mitochondrial disorders. Hum Mol Genet 18: 1805–1812. relationships in a neuroblastoma cell line. Biochim Biophys Acta
1830: 2891–2898.
Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert
KM et al. (2008). Short-term effects of coenzyme Q10 in progressive Tadaishi M, Miura S, Kai Y, Kawasaki E, Koshinaka K, Kawanaka K
supranuclear palsy: a randomized, placebo-controlled trial. Mov et al. (2011). Effect of exercise intensity and AICAR on
Disord 23: 942–949. isoform-specific expressions of murine skeletal muscle PGC-1alpha
mRNA: a role of beta(2)-adrenergic receptor activation. Am J
Steiner JL, Murphy EA, McClellan JL, Carmichael MD, Davis JM Physiol Endocrinol Metab 300: E341–E349.
(2011). Exercise training increases mitochondrial biogenesis in the
brain. J Appl Physiol 111: 1066–1071. Tan EK, Skipper LM (2007). Pathogenic mutations in Parkinson
disease. Hum Mutat 28: 641–653.
Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J et al.
(2007). Randomized, double-blind, placebo-controlled trial on Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E
symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch et al. (2003). Idebenone treatment fails to slow cognitive decline in
Neurol 64: 938–944. Alzheimer’s disease. Neurology 61: 1498–1502.
Viollet B, Guigas B, Leclerc J, Hebrard S, Lantier L, Mounier R et al. Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC
(2009). AMP-activated protein kinase in the regulation of hepatic (2011). Efficient elimination of cancer cells by
energy metabolism: from physiology to therapeutic perspectives. deoxyglucose-ABT-263/737 combination therapy. PLoS ONE 6:
Acta Physiol (Oxf) 196: 81–98. e24102.
Wang X, Su B, Lee HG, Li X, Perry G, Smith MA et al. (2009). Youle RJ, Narendra DP (2011). Mechanisms of mitophagy. Nat Rev
Impaired balance of mitochondrial fission and fusion in Mol Cell Biol 12: 9–14.
Alzheimer’s disease. J Neurosci 29: 9090–9103.
Young AJ, Johnson S, Steffens DC, Doraiswamy PM (2007).
Warburg O (1956). On the origin of cancer cells. Science 123:
Coenzyme Q10: a review of its promise as a neuroprotectant. CNS
309–314.
Spectr 12: 62–68.
Wenz T, Williams SL, Bacman SR, Moraes CT (2010). Emerging
therapeutic approaches to mitochondrial diseases. Dev Disabil Res Zemke D, Azhar S, Majid A (2007). The mTOR pathway as a
Rev 16: 219–229. potential target for the development of therapies against
neurological disease. Drug News Perspect 20: 495–499.
Wenz T, Wang X, Marini M, Moraes CT (2011). A metabolic shift
induced by a PPAR panagonist markedly reduces the effects of Zhu X, Perry G, Smith MA, Wang X (2013). Abnormal
pathogenic mitochondrial tRNA mutations. J Cell Mol Med 15: mitochondrial dynamics in the pathogenesis of Alzheimer’s disease.
2317–2325. J Alzheimers Dis 33 (Suppl. 1): S253–S262.